Bio-Techne Corp
NASDAQ:TECH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bio-Techne Corp
NASDAQ:TECH
|
US |
|
C
|
Coca-Cola Co
XMUN:CCC3
|
US |
|
Charter Communications Inc
NASDAQ:CHTR
|
US |
|
BASF SE
F:BASA
|
DE |
|
InfuSystem Holdings Inc
F:1TZ
|
US |
|
A
|
Apple Inc
XMUN:APC
|
US |
|
IRSA Inversiones y Representaciones SA
F:IRY
|
AR |
|
Gofore Oyj
F:1E2
|
FI |
|
S
|
Sumitomo Corp
XMUN:SUMA
|
JP |
|
P
|
Premiere Horizon Alliance Corp
XPHS:PHA
|
PH |
Earnings Calls
Last Earnings Call
Revenue: Bio-Techne reported Q3 revenue of $311.4 million, down 2% year over year, with underlying organic growth of 2% after adjusting for timing and other one-time items.
Margins: Adjusted operating margin was 34.2%, up 310 basis points sequentially, showing strong profitability even in a mixed demand environment.
Biotech Weakness: Emerging biotech spending was softer than expected and declined high single digits, which management said was the main reason the quarter came in below its underlying trend.
Strong Spots: Large pharma grew low double digits for its sixth straight quarter, China posted its fourth consecutive quarter of organic growth, and Spatial Biology delivered mid-teens growth.
Outlook: Management expects Q4 organic growth to be approximately flat, with low single-digit underlying growth excluding the temporary cell therapy headwind.
FY27 View: Management said it would be disappointed not to deliver at least mid-single-digit growth in fiscal 2027, citing improving biotech funding, a steadier academic market and easier comparisons.